

# Origin of Cardiac Troponin T Elevations in Chronic Kidney

Citation for published version (APA):

van der Linden, N., Cornelis, T., Kimenai, D. M., Klinkenberg, L. J. J., Hilderink, J. M., Luck, S., Litjens, E. J. R., Peeters, F. E. C. M., Streng, A. S., Breidhardt, T., van Loon, L. J. C., Bekers, O., Kooman, J. P., Westermark, P. O., Mueller, C., & Meex, S. J. R. (2017). Origin of Cardiac Troponin T Elevations in Chronic Kidney. *Circulation*, 136(11), 1073-1075. <https://doi.org/10.1161/CIRCULATIONAHA.117.029986>

## Document status and date:

Published: 12/09/2017

## DOI:

[10.1161/CIRCULATIONAHA.117.029986](https://doi.org/10.1161/CIRCULATIONAHA.117.029986)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease

**P**lasma concentrations of cardiac troponins, the preferred biomarkers for the diagnosis of acute myocardial infarction, are often persistently elevated in patients with chronic kidney disease (CKD). The origin of these elevations is unknown: Is it the heart, by increased release, or the kidneys, by decreased renal elimination? In clinical practice, this equivocal view on troponin elevations in patients with reduced glomerular clearance underlies countless clinical discussions among physicians and may delay rapid initiation of adequate treatment when these patients present with chest pain.

In the present study, we aimed to discriminate between increased cardiac release and reduced renal elimination as the main process underlying this phenomenon. Specifically, we used the recently demonstrated rhythmic diurnal oscillation pattern of troponin T as a model to assess the contribution of impaired renal elimination to persistently elevated cardiac troponin levels in patients with CKD.<sup>1</sup> The diurnal troponin T rhythm is characterized by gradually decreasing concentrations throughout daytime and rising concentrations during nighttime.<sup>1</sup> If decreased renal clearance, and not increased production, is the key driver of elevated troponins in patients with CKD, the increased half-life and subsequent accumulation of cardiac troponin T will fade its diurnal rhythm.<sup>2</sup>


To test this hypothesis, we conducted hourly blood sampling over 1 full day (24 hours) in 44 individuals: 20 reference subjects (16 male, 4 female; median estimated glomerular filtration rate [eGFR] 82.8 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup> [68.0–92.7 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>]) and 24 subjects with impaired renal function (eGFR <60 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>; 17 male, 7 female; median eGFR, 18.3 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup> [14.2–32.2 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>]). All included subjects had detectable cardiac troponin T concentrations (median concentration reference group, 14.1 ng/L [10.4–20.6 ng/L] versus 20.5 ng/L [18.0–24.6 ng/L] in subjects with impaired renal function; *P*=0.009). With the use of cosinor rhythmometry, diurnal troponin T curves were fitted and expressed as deviation (percent) from their 24-hour mesor troponin concentration. Cardiac troponin T concentrations over the day in the reference subjects fitted a cosinor model (Figure, A; individual curves<sup>1</sup>: range *R*<sup>2</sup>=0.23–0.91; all *P*<0.001). Next, we used a validated mathematical framework on the dynamics of diurnal rhythms to examine the hypothetical effect of prolonged elimination times caused by impaired renal function on the rhythmic oscillation of cardiac troponin T. This model is extensively described elsewhere.<sup>2</sup> As depicted in Figure, B, an 80% decrease in renal elimination (based on the eGFR in the CKD group) would theoretically reduce the cardiac troponin T amplitude on the group level from 12% to 8%. Finally, to examine whether the predicted faded rhythm was evident in subjects who actually have an 80% decreased renal elimination rate, the diurnal troponin T rhythm was analyzed in 24 participants with impaired renal function. In Figure, C, we demonstrate identical cosinor patterns for all subjects with amplitudes similar to those observed in the reference group (12.0±0.5% versus 11.4±0.5%; *P*=0.53), excluding a major

**Noreen van der Linden, MD**  
**Tom Cornelis, PhD**  
**Dorien M. Kimenai, MSc**  
**Lieke J.J. Klinkenberg, PhD**  
**Judith M. Hilderink, MD**  
**Sarah Lück, MSc**  
**Elisabeth J. R. Litjens, MD**  
**Frederique E.C.M. Peeters, MD**  
**Alexander S. Streng, PhD**  
**Tobias Breidhardt, MD**  
**Luc J.C. van Loon, PhD**  
**Otto Bekers, PhD**  
**Jeroen P. Kooman, PhD**  
**Pål O. Westermark, PhD**  
**Christian Mueller, MD**  
**Steven J.R. Meex, PhD**

**Correspondence to:** Steven J.R. Meex, PhD, Department of Clinical Chemistry, Central Diagnostic Laboratory, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, Netherlands. E-mail [steven.meex@mumc.nl](mailto:steven.meex@mumc.nl)

**Key Words:** kidney diseases  
 ■ troponin

© 2017 American Heart Association, Inc.



**Figure.** The effect of decreased estimated glomerular filtration rate (eGFR) on the diurnal rhythm of cardiac troponin T (cTnT).

The diurnal rhythm of cTnT. **A**, All individual data points and cosine curve on the group level of the reference population. **B**, The mathematically predicted cosine curve for a group with an 80% decrease in eGFR. **C**, All individual data points and cosine curve on the group level for the group with decreased renal function.

role for impaired renal elimination as the main cause of persistently elevated cardiac troponin T levels in CKD. The observed rhythm was not abrogated by the use of loop diuretics, nor was the circadian pattern of cardiac troponin T correlated with the circadian pattern of 24-hour blood pressure measurements, cortisol, thyroid-stimulating hormone, or testosterone (data not shown). Meanwhile, the amplitude of cystatin C, an analyte that also has a diurnal rhythm and with an established renal elimination route, was significantly faded among subjects with decreased renal function compared with the reference group. Its mathematically predicted amplitude in subjects with impaired renal function matched the observed amplitude in these subjects, supporting the validity of the mathematical model (amplitude cystatin c reference group,  $3.9 \pm 0.2\%$  versus  $1.7 \pm 0.2\%$  in subjects with impaired renal function;  $P < 0.001$ ; mathematically predicted amplitude, 2%).

Although we cannot exclude small amounts of renal elimination of cardiac troponin T,<sup>3</sup> the nonfading diurnal rhythm in subjects with decreased eGFR implies that diminished renal clearance with subsequent accumulation of troponin is not the key driver of high troponin levels in CKD. Accordingly, our findings strongly suggest that factors other than renal elimination, most likely increased release of cardiac troponins from the heart as a result of (subclinical) myocardial injury, contribute to elevated troponin T levels in subjects with CKD. This is in line with epidemiological evidence showing strong and robust associations between decreased renal function and cardiovascular risk.<sup>4,5</sup>

In conclusion, our results indicate that impaired renal elimination is not the main driver behind persistently elevated cardiac troponin T levels and emphasize the importance of extensive diagnostic workup in all patients with elevated cardiac troponin concentrations, regardless of their eGFR.

The present study was carried out according to the principles of Helsinki, approved by the Institutional Review Board and Ethics Committee, and registered at ClinicalTrials.gov (Unique identifiers: NCT02091427 and NCT02210897). All participants provided written informed consent.

## SOURCES OF FUNDING

This study was funded by a research grant from Stichting de Weijerhorst.

## DISCLOSURES

None.

## AFFILIATIONS

From Department of Clinical Chemistry, Central Diagnostic Laboratory (N.v.d.L., D.M.K., L.J.J.K., J.M.H., A.S.S., O.B., S.J.R.M.) and Department of Cardiology (F.E.C.M.P.), Cardiovascular Research Institute Maastricht, Department of Internal Medicine, Division of Nephrology (T.C., E.J.R.L., J.P.K.), and Department of Human Biology and Movement Sciences, School of Nutrition and Translational Research in Metabolism (L.J.C.v.L.), Maastricht University Medical Center, The Netherlands; Institute for Theoretical Biology, Charité-Universitätsmedizin, Berlin, Germany (S.L.); Department of Internal Medicine (T.B.), Department of Cardiology (C.M.), and Cardiovascular Research Institute Basel (T.B., C.M.), University Hospital Basel, University of Basel, Switzerland; and Biomathematics and Bioinformatics Unit, Institute of Genetics and Biometry, Leibniz Institute for Farm Animal Biology, Dummerstorf, Germany (P.O.W.). Dr Cornelis is currently at Department of Nephrology, Jessa Hospital, Hasselt, Belgium. Dr Klinkenberg is currently at Clinical Laboratory, Catharina Hospital, Eindhoven, The Netherlands.

## FOOTNOTES

*Circulation* is available at <http://circ.ahajournals.org>.

## REFERENCES

1. Klinkenberg LJ, Wildi K, van der Linden N, Kouw IW, Niens M, Twerenbold R, Rubini Gimenez M, Puelacher C, Daniel Neuhaus J, Hillinger P, Nestelberger T, Boeddinghaus J, Grimm K, Sabti Z, Bons JA, van Suijlen JD, Tan FE, Ten Kate J, Bekers O, van Loon LJ, van Dieijen-Visser MP, Mueller C, Meex SJ. Diurnal rhythm of cardiac troponin: consequences for the diagnosis of acute myocardial infarction. *Clin Chem*. 2016;62:1602–1611. doi: 10.1373/clinchem.2016.257485.
2. Lück S, Thurley K, Thäben PF, Westermark PO. Rhythmic degradation explains and unifies circadian transcriptome and proteome data. *Cell Rep*. 2014;9:741–751. doi: 10.1016/j.celrep.2014.09.021.
3. Fridén V, Starnberg K, Muslimovic A, Ricksten SE, Bjurman C, Forsgard N, Wickman A, Hammarsten O. Clearance of cardiac troponin T with and without kidney function. *Clin Biochem*. 2017;50:468–474. doi: 10.1016/j.clinbiochem.2017.02.007.
4. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RT; PREVEND Study Group. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. *Eur Heart J*. 2012;33:2272–2281. doi: 10.1093/eurheartj/ehs163.
5. Oluleye OW, Folsom AR, Nambi V, Lutsey PL, Ballantyne CM; ARIC Study Investigators. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. *Ann Epidemiol*. 2013;23:66–73. doi: 10.1016/j.annepidem.2012.11.004.